TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Sun Pharma Adv.res.co.ltd
SPARC

Sun Pharma Adv.res.co.ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 65/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹209.05

Change

+5.07 (2.49%)

Open

₹204.4

Prev. Close

₹203.98

Day High

₹212.0

Day Low

₹203.6

Volume Analysis

Traded

2,233,858

Delivered

746,829

Delivery %

33.43%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (279.0%)
  • •Strong operating margin (85.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year revenue growth (98.8%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹221.24 ₹216.62 ₹212.84 ₹208.22 ₹204.44 ₹199.82 ₹196.04
Fibonacci ₹216.62 ₹213.41 ₹211.43 ₹208.22 ₹205.01 ₹203.03 ₹199.82
Camarilla ₹211.36 ₹210.59 ₹209.82 ₹208.22 ₹208.28 ₹207.51 ₹206.74

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+54.82%

1 Week

+6.6%

1 Month

+0.65%

3 Months

-10.95%

6 Months

+73.72%

1 Year

+58.66%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹210.89

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

116.95%

Net margin 82.98% × asset turnover 0.87x × equity multiplier 1.62x

Company Overview

Sector

Healthcare

Market Cap

₹6,784 Cr

P/E (TTM)

4.25

ROE

279.0%

Book Value

₹41.3

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Sun Pharma Adv.res.co.ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Growth (100/100), while Risk & Volatility (11/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (279.0%); strong operating margin (85.0%). Strong 3-year revenue growth (98.8%).

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

93

Growth

100

Valuation

42

Cash Flow

32

Corporate Governance

56

Momentum

56

Institutional Ownership

23

Business Quality

100

Risk & Volatility

11

Liquidity

63

From Screener.in

  • −Stock is trading at 5.07 times its book value
  • −Working capital days have increased from -768 days to 215 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Closure of Trading Window 25 Sep

Trading window closes from October 1, 2026 until 48 hours after Q2 and half-year results.

Filing Of Application For Reclassification With Stock Exchanges 13 Aug

SPARC filed application for promoter-group reclassification to public under Regulation 31A on August 13, 2026.

Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Aug 11 Aug
Shareholder Meeting / Postal Ballot-Outcome of AGM 10 Aug

21st AGM on Aug 10, 2026 approved all resolutions, including appointment of Anil Raghavan as MD & CEO.

Announcement under Regulation 30 (LODR)-Monitoring Agency Report 10 Aug

Q1 FY27 monitoring report for ₹599.98 crore warrants issue shows no deviation and full loan repayment use.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 24 21 14 17 17 13 15 27 10 8 8 1,853 40
Expenses + 126 113 116 122 110 116 89 80 62 74 65 80 74
Operating Profit -102 -91 -103 -106 -93 -103 -74 -53 -52 -66 -57 1,773 -34
OPM % -427.0% -432.0% -740.0% -639.0% -555.0% -800.0% -494.0% -196.0% -540.0% -836.0% -670.0% 96.0% -85.0%
Other Income + 10 8 6 4 2 0 0 0 9 0 -12 2 24
Interest 0 0 0 1 1 1 3 5 6 8 9 12 8
Depreciation 3 3 3 3 3 3 3 3 3 3 3 2 2
Profit before tax -95 -86 -100 -105 -96 -107 -79 -61 -52 -76 -80 1,761 -21
Tax % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -1.0% 0.0% 0.0% 0.0% 0.0% 1.0%
Net Profit + -95 -86 -100 -106 -96 -107 -80 -60 -52 -76 -80 1,761 -21
EPS in Rs -3 -3 -3 -3 -3 -3 -2 -2 -2 -2 -2 54 -1
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 239 76 72 1,879 1,909
Expenses + 453 478 395 280 293
Operating Profit -214 -402 -323 1,599 1,617
OPM % -90.0% -532.0% -450.0% 85.0% 85.0%
Other Income + 11 29 2 -2 13
Interest 8 2 9 34 36
Depreciation 12 13 12 10 10
Profit before tax -223 -387 -343 1,553 1,584
Tax % 0.0% 0.0% 0.0% 0.0% —
Net Profit + -223 -387 -343 1,553 1,584
EPS in Rs -7 -12 -11 48 49
Dividend Payout % 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 480 93 -249 1,306
Borrowings + 16 61 269 559
Other Liabilities + 302 328 284 273
Total Liabilities 830 515 336 2,171
Fixed Assets + 106 108 99 85
CWIP 27 44 54 72
Investments 291 2 0 0
Other Assets + 406 362 183 2,014
Total Assets 830 515 336 2,171
Equity Capital 32 32 32 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -69 -429 -360 -239
Cash from Investing Activity + -548 392 158 -23
Cash from Financing Activity + 617 42 199 261
Net Cash Flow -1 5 -3 -1
CFO/OP 35 106 114 -17
Free Cash Flow -84 -455 -370 -262

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 65.68% → 65.68%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 29.99% 30.36% 30.41% 31.51% 31.96% 31.47% 31.76% 31.88% 31.52% 31.51% 31.41% 30.34%
Promoters 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.67% 65.67% 65.67% 65.67% 65.68%
FII 3.67% 3.3% 3.24% 2.64% 2.15% 2.23% 1.45% 1.47% 1.76% 2.04% 2.04% 3.9%
DII 0.65% 0.67% 0.67% 0.17% 0.21% 0.64% 1.13% 0.97% 1.05% 0.78% 0.88% 0.09%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sun Pharma Adv.res.co.ltd (this stock) 6,784 4.25 5.06 279.0%
Kovai Medical Center & Ho 6,653 115.0 23.07 22.2%
Morepen Lab. Ltd 6,596 56.2 5.26 5.33%
Nephrocare Health Serv L 7,005 82.3 6.28 8.83%
Symbiotec Pharmalab Ltd 6,447 64.8 — 11.7%
Orchid Pharma Limited 6,377 353.0 3.55 1.49%
Sanofi India Limited 7,232 16.4 8.4 47.1%

Which Mutual Funds Hold Sun Pharma Adv.res.co.ltd?

Frequently Asked Questions about Sun Pharma Adv.res.co.ltd

Community Sentiment

What are other investors saying about Sun Pharma Adv.res.co.ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.